Literature DB >> 24512292

Highly potent HCV NS4B inhibitors with activity against multiple genotypes.

Barton Phillips1, Ruby Cai, William Delaney, Zhimin Du, Mingzhe Ji, Haolun Jin, Johnny Lee, Jiayao Li, Anita Niedziela-Majka, Michael Mish, Hyung-Jung Pyun, Joe Saugier, Neeraj Tirunagari, Jianhong Wang, Huiling Yang, Qiaoyin Wu, Chris Sheng, Catalin Zonte.   

Abstract

The exploration of novel inhibitors of the HCV NS4B protein that are based on a 2-oxadiazoloquinoline scaffold is described. Optimization to incorporate activity across genotypes led to a potent new series with broad activity, of which inhibitor 1 displayed the following EC50 values: 1a, 0.08 nM; 1b, 0.10 nM; 2a, 3 nM; 2b, 0.6 nM, 3a, 3.7 nM; 4a, 0.9 nM; 6a, 3.1 nM.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24512292     DOI: 10.1021/jm401646w

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  4 in total

1.  Palladium-Catalyzed Arylation of Fluoroalkylamines.

Authors:  Andrew T Brusoe; John F Hartwig
Journal:  J Am Chem Soc       Date:  2015-06-29       Impact factor: 15.419

2.  Encoded library technology screening of hepatitis C virus NS4B yields a small-molecule compound series with in vitro replicon activity.

Authors:  Christopher Arico-Muendel; Zhengrong Zhu; Hamilton Dickson; Derek Parks; Jesse Keicher; Jianghe Deng; Leah Aquilani; Frank Coppo; Todd Graybill; Kenneth Lind; Andrew Peat; Michael Thomson
Journal:  Antimicrob Agents Chemother       Date:  2015-03-30       Impact factor: 5.191

3.  Preclinical Characterization and In Vivo Efficacy of GSK8853, a Small-Molecule Inhibitor of the Hepatitis C Virus NS4B Protein.

Authors:  Jeffrey J Pouliot; Michael Thomson; Mi Xie; Joseph Horton; John Johnson; David Krull; Amanda Mathis; Yoshio Morikawa; Derek Parks; Richard Peterson; Takashi Shimada; Elizabeth Thomas; Jessica Vamathevan; Stephanie Van Horn; Zhiping Xiong; Robert Hamatake; Andrew J Peat
Journal:  Antimicrob Agents Chemother       Date:  2015-08-10       Impact factor: 5.191

Review 4.  Current therapy for chronic hepatitis C: The role of direct-acting antivirals.

Authors:  Guangdi Li; Erik De Clercq
Journal:  Antiviral Res       Date:  2017-02-24       Impact factor: 5.970

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.